Mary K. Buss

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso et al. · The Lancet · 2017 · 1.7K citations · Full text

Medicine, Gynecology, Oncology +12

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

Joyce F. Liu, William T. Barry, Michael J. Birrer et al. · The Lancet Oncology · 2014 · 584 citations · Full text

Medicine, Gynecology, Oncology +16

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

Panagiotis A. Konstantinopoulos, William T. Barry, Michael J. Birrer et al. · The Lancet Oncology · 2019 · 262 citations

Medicine, Oncology, Pharmacology +13

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer

Panagiotis A. Konstantinopoulos, Weixiu Luo, Joyce F. Liu et al. · Journal of Clinical Oncology · 2019 · 218 citations · Full text

Medicine, Immunology, Oncology +17

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

J.F. Liu, William T. Barry, Michael J. Birrer et al. · Annals of Oncology · 2019 · 189 citations · Full text

Medicine, Oncology, Pharmacotherapy +16